Genetic scissors: A new era in gene therapy

Abstract

The article gives a brief description of gene therapy, a new technology for treating genetic disorders, and the revolutionary effect of gene editing techniques which include CRISPR-Cas9. The introduction serves as a basis by covering the basics of gene therapy and the revolutionary aspect of genetic scissors as surgical instruments for genetic editing. In a brief overview, gene therapy is explained, which is meant to correct hereditary failing at their source, and subsequently ZFNs (zinc finger nucleases), CRISPR-Cas9 and TALENs are explored. The diverse applications are emphasized in the review, and the paper explores how genetic scissors are utilized in gene repair (correction of mutations which are responsible for diseases such as atherosclerosis, cancer, bone and cartilage repair etc.). It highlights the potential of genetic scissors in changing the therapeutic landscape. The future scope section provides a detailed illustration of the ever-changing capabilities and possibilities of the technology, thereby offering a glimpse of what may be around the next corner. To sum up, the review discusses the ground-breaking role of genetic scissors in gene therapy and stress the necessity of continuous research, ethical standards and collaboration to successfully apply these methods in personalized medicine and healthcare.

Keywords

• Gene therapy
• genetic scissors
• DNA modification
• CRISPR-Cas9
• disease treatment

References

1. Young P. Treatment to cure: Advancing AAV gene therapy manufacture. Drug Discov Today. 2023; 28(7): 103610. https://doi.org/10.1016/j.drudis.2023.103610
2. Yue NN, Xu HM, Xu J, Zhu MZ, Zhang Y, Tian CM. Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives. Mol Ther Oncolytics. 2023; 30: 193-215. https://doi.org/10.1016/j.omto.2023.08.007
3. Bhatt B, García-Díaz, Foight GW. Synthetic transcription factor engineering for cell and gene therapy. Trends Biotechnol. 2024; 42(4): 449-463. https://doi.org/10.1016/j.tibtech.2023.09.010
4. Mücke MM, Fong S, Foster GR, Lillicrap D, Miesbach W. Adeno-associated viruses for gene therapy – clinical implications and liver-related complications, a guide for hepatologists. J Hepatol. 2024; 80(2): 352-361. https://doi.org/10.1016/j.jhep.2023.10.029
5. Zhang Y, Wu ZY. Gene therapy for monogenic disorders: challenges, strategies, and perspectives. J Genet Genomics. 2024;51(2):133-143. https://doi.org/10.1016/j.jgg.2023.08.001
6. Kell P, Sidhu R, Qian M, Mishra S, Nicoli ER, D'Souza P. A pentasaccharide for monitoring pharmacodynamic response to gene therapy in GM1 gangliosidosis. eBioMedicine. 2023; 92: 104627. https://doi.org/10.1016/j.ebiom.2023.104627
7. Liu F. The science and practice of current environmental risk assessment for gene therapy: a review. Cytotherapy. 2024; 26(7): 686-699. https://doi.org/10.1016/j.jcyt.2024.04.067
8. Saravanan CR, Eisa RFH, Gaviria E, Algubari A, Chandrasekar KK, Inban P, Prajjwal P, Bamba H. The efficacy and safety of gene therapy approaches in Parkinson's disease: A systematic review. Dis Mon. 2024; 70(7): 101754. https://doi.org/10.1016/j.disamonth.2024.101754

9. Querin G, Colella M. Gene therapy for primary myopathies: literature review and prospects. Arch Pediatr. 2023; 30(8- 1): 8S18-8S23. https://doi.org/10.1016/s0929-693x(23)00223-3
10. Goraltchouk A, Lourie J, Hollander JM, Rosen G, Fujishiro AA, Luppino F. Development and characterization of a first-in-class adjustable-dose gene therapy system. Gene. 2024; 919: 148500. https://doi.org/10.1016/j.gene.2024.148500
11. Yeung J, Liao A, Shaw M, Silva S, Vetharoy W, Rico DL. Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant. Mol Ther. 2024; 32(6): 1672-1686. https://doi.org/10.1016/j.ymthe.2024.03.032
12. Butterfield JSS, Li X, Arisa S, Kwon K, Daniell H. Potential role for oral tolerance in gene therapy. Cell Immunol. 2023; 391-392: 104742. https://doi.org/10.1016/j.cellimm.2023.104742
13. Ferrari S, Valeri E, Anastasia C, Scala S, Aprile A, Micco RD. Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy. Cell Stem Cell. 2023; 30(5): 549-570. https://doi.org/10.1016/j.stem.2023.04.014
14. Blay E, Hardyman E, Morovic W. PCR-based analytics of gene therapies using adeno-associated virus vectors: Considerations for cGMP method development. Mol Ther Methods Clin Dev. 2023;31:101132. https://doi.org/10.1016/j.omtm.2023.101132
15. Nykänen AI, Keshavjee S, Liu M. Creating superior lungs for transplantation with next-generation gene therapy during ex vivo lung perfusion. J Heart Lung Transplant. 2024; 43(5): 839-848. https://doi.org/10.1016/j.healun.2024.01.016
16. Nykänen AI, Keshavjee S, Liu M. Creating superior lungs for transplantation with next-generation gene therapy during ex vivo lung perfusion. J Heart Lung Transplant. 2024; 43(5): 839-848. https://doi.org/10.1016/j.healun.2024.01.016
17. Silver E, Argiro A, Hong K, Adler E. Gene therapy vector-related myocarditis. Int J Cardiol. 2024; 398: 131617. https://doi.org/10.1016/j.ijcard.2023.131617
18. Sasaki N, Kok CY, Westhaus A, Alexander IE, Lisowski L, Kizana E. In search of adeno-associated virus vectors with enhanced cardiac tropism for Gene Therapy. Heart Lung Circ. 2023; 32(7): 816-824. https://doi.org/10.1016/j.hlc.2023.06.704
19. Rubanyi GM. The future of human gene therapy. Mol Aspects Med. 2001; 22(3): 113-42. https://doi.org/10.1016/s0098-2997(01)00004-8
20. Kunze-Küllmer M, Goonewardene A, Kili S, Theoharis S, Rivers P. Cell and gene therapy investment: evolution and future outlook on investor perspectives. Cytotherapy. 2024; 26(7): 672-680. https://doi.org/10.1016/j.jcyt.2024.02.017
21. Gonçalves GA, Paiva RD. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo). 2017; 15(3): 369- 75. https://doi.org/10.1590/S1679-45082017RB4024
22. Feuerbach FJ, Crystal RG. Progress in human gene therapy. Kidney Int. 1996; 49(6): 1791-1794. https://doi.org/10.1038/ki.1996.269
23. Ikonomou L, Cuende N, Forte M, Grilley BJ, Levine AD, Munsie M. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products. Cytotherapy. 2023; 25(9): 920-929. https://doi.org/10.1016/j.jcyt.2023.03.002
24. Shoti J, Qing K, Keeler GD, Duan D, Byrne BJ, Srivastava A. Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy. Mol Ther Methods Clin Dev. 2023; 31: 101147. https://doi.org/10.1016/j.omtm.2023.101147
25. Asmamaw M, Zawdie B. Mechanism and applications of CRISPR/Cas-9-mediated genome editing. Biol Targets Ther. 2021; 15: 353-361. https://doi.org/10.2147/BTT.S326422
26. Ishino Y, Krupovic M, Forterre P. History of CRISPR-Cas from encounter with a mysterious repeated sequence to genome editing technology. J Bacteriol. 2018; 200(7): 10-128. https://doi.org/10.1128/JB.00580-17
27. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013; 8(11): 2281-2308. https://doi.org/10.1038/nprot.2013.143
28. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014; 346(6213): 1258096. https://doi.org/10.1126/science.1258096
29. Porteus MH, Carroll D. Gene targeting using zinc finger nucleases. Nat Biotechnol. 2005; 23(8): 967-973. https://doi.org/10.1038/nbt1125
30. Carroll D. Genome engineering with zinc-finger nucleases. Genetics. 2011;188(4):773-782. https://doi.org/10.1534/genetics.111.131433
31. Harmatz P, Prada CE, Burton BK, Lau H, Kessler CM, Cao L, Falaleeva M, Villegas AG, Zeitler J, Meyer K, Miller W. First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia B. Mol Ther. 2022; 30(12): 3587-3600. https://doi.org/10.1016/j.ymthe.2022.10.010
32. Ragni MV, Mead H, Jong YPD, Kaczmarek R, Leavitt AD. Optimizing Liver Health Before and After Gene Therapy for Hemophilia A. Blood Adv. 2024; 8(19): 5203-5212. https://doi.org/10.1182/bloodadvances.2024013059
33. Kashiwakura Y, Endo K, Ugajin A, Kikuchi T, Hishikawa S, Nakamura H. Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy. Mol Ther Methods Clin Dev. 2023; 30: 502-514. https://doi.org/10.1016/j.omtm.2023.08.016
34. Kumar S, Schroeder JA, Shi Q. Platelet-targeted gene therapy induces immune tolerance in hemophilia and beyond. J Thromb Haemost. 2024; 22(1): 23-34. https://doi.org/10.1016/j.jtha.2023.07.025
35. Cathomen T, Joung JK. Zinc-finger nucleases: the next generation emerges. Mol Ther. 2008; 16(7): 1200-1207. https://doi.org/10.1038/mt.2008.114
36. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010; 11(9): 636-646. https://doi.org/10.1038/nrg2842
37. Schwotzer N, Sissy CE, Desguerre I, Frémeaux-Bacchi V, Servais L and Fakhouri F. Thrombotic Microangiopathy as an Emerging Complication of Viral Vector–Based. Kidney Int Rep. 2024; 9(7): 1995-2005. https://doi.org/10.1016/j.ekir.2024.04.024
38. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2013; 14(1): 49-55. https://doi.org/10.1038/nrm3486
39. Bhardwaj A, Nain V. TALENs—an indispensable tool in the era of CRISPR: a mini review. J Genet Eng Biotechnol. 2021;19(1):125. https://doi.org/10.1186/s43141-021-00225-z
40. Becker S, Boch J. TALE and TALEN genome editing technologies. Gene and Genome Editing. 2021; 2: 100007. https://doi.org/10.1016/j.ggedit.2021.100007
41. Sakuma T, Hosoi S, Woltjen K, Suzuki K, Kashiwagi K, Wada H, Ochiai H, Miyamoto T, Kawai N, Sasakura Y, Matsuura S, Okada Y, Kawahara A, Hayashi S, Yamamoto T. Efficient TALEN construction and evaluation methods for human cell and animal applications. Genes Cells. 2013;18(4):315-326. https://doi.org/10.1111/gtc.12037.
42. Galy A, Dewannieux M. Recent advances in hematopoietic gene therapy for genetic disorders. Arch Pediatr. 2023; 30(8-1): 8S24-8S31. https://doi.org/10.1016/s0929-693x(23)00224-5
43. Bougioukli S, Evans CH, Alluri RK, Ghivizzani SC, Lieberman JR. Gene therapy to enhance bone and cartilage repair in orthopaedic surgery. Curr Gene Ther. 2018; 18(3): 154-170. https://doi.org/10.2174/1566523218666180410152842
44. Longo UG, Petrillo S, Franceschetti E, Berton A, Maffulli N, Denaro V. Stem cells and gene therapy for cartilage repair. Stem Cells Int. 2012;2012:168385. https://doi.org/10.1155/2012/168385
45. Cucchiarini M, Madry H. Gene therapy for cartilage defects. J Gene Med. 2005; 7(12): 1495-1509. https://doi.org/10.1002/jgm.824
46. Defois A, Bon N, Mével M, Deniaud D, Maugars Y, Guicheux J. Gene therapies for osteoarthritis: progress and prospects. JCJP. 2024; 4(2): 100186. https://doi.org/10.1016/j.jcjp.2024.100186
47. Gelse K, von der Mark K, Aigner T, Park J, Schneider H. Articular cartilage repair by gene therapy using growth factor–producing mesenchymal cells. Arthritis Rheum. 2003; 48(2): 430-441. https://doi.org/10.1002/art.10759
48. El-Aneed A. Current strategies in cancer gene therapy. Eur J Pharmacol. 2004; 498(1-3): 1-8. https://doi.org/10.1016/j.ejphar.2004.06.054
49. Słyk Z, Wrzesień R, Małecki M. Adeno-associated virus vector hydrogel formulations for brain cancer gene therapy applications. Biomed Pharmacother. 2024; 170: 116061. https://doi.org/10.1016/j.biopha.2023.116061
50. Qi L, Li G, Li P, Wang H, Fang X, He T. Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology. Genes Dis. 2024; 11(4): 101155. https://doi.org/10.1016/j.gendis.2023.101155
51. Meng H, Nan M, Li Y, Ding Y, Yin Y, Zhang M. Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer. Front Endocrinol. 2023; 14: 1148412. https://doi.org/10.3389/fendo.2023.1148412
52. Rayati M, Mansouri V, Ahmadbeigi N. Gene therapy in glioblastoma multiforme: Can it be a role changer. Heliyon. 2024; 10(5): e27087. https://doi.org/10.1016/j.heliyon.2024.e27087
53. Amer MH. Gene therapy for cancer: present status and future perspective. Mol Cell Ther. 2014; 2: 27. https://doi.org/10.1186/2052-8426-2-27
54. Ma Y, Liao J, Cheng H, Yang Q, Yang H. Advanced gene therapy system for the treatment of solid tumour: A review. Mater Today Bio. 2024; 27: 101138. https://doi.org/10.1016/j.mtbio.2024.101138
55. Kivelä AM, Huusko J, Ylä-Herttuala S. Prospect and progress of gene therapy in treating atherosclerosis. Expert Opin Biol Ther. 2015; 15(12): 1699-1712. https://doi.org/10.1517/14712598.2015.1084282
56. Lehrke M, Lebherz C. AAV-mediated gene therapy for Atherosclerosis. Curr. Atheroscler. Rep. 2014; 16(9): 1-7. https://doi.org/10.1007/s11883-014-0434-0
57. Argiro A, Bui Q, Hong KN, Ammirati E, Olivotto I. Applications of Gene Therapy in Cardiomyopathies. JACC Heart Fail. 2024; 12(2): 248-260. https://doi.org/10.1016/j.jchf.2023.09.015
58. Tenkumo T, Sáenz JR, Nakamura K, Shimizu Y, Sokolova V, Epple M, Kamano Y, Egusa H, Sugaya T, Sasaki K. Prolonged release of bone morphogenetic protein-2 in vivo by gene transfection with DNA-functionalized calcium phosphate nanoparticle-loaded collagen scaffolds. Mater Sci Eng C. 2018; 92: 172-83. https://doi.org/10.1016/j.msec.2018.06.047
59. Madry H, Orth P, Cucchiarini M. Gene therapy for cartilage repair. Cartilage. 2011; 2(3): 201-225. https://doi.org/10.1177/1947603510392914
60. Wong MS, Hawthorne WJ, Manolios N. Gene therapy in diabetes. Self/nonself. 2010; 1(3): 165-175. https://doi.org/10.4161/self.1.3.12643
61. Xu R, Li H, Lai-yin T, Hsiang-fu K, Lu H, Lam KS. Diabetes gene therapy: potential and challenges. Curr Gene Ther. 2003; 3(1): 65-82. https://doi.org/10.2174/1566523033347444
62. Ishibashi Y, Sung CYW, Grati M, Chien W. Immune responses in the mammalian inner ear and their implications for AAV-mediated inner ear gene therapy. Hear Res. 2023; 432: 108735. https://doi.org/10.1016/j.heares.2023.108735
63. Callejas D, Mann CJ, Ayuso E, Lage R, Grifoll I, Roca C, Andaluz A, Ruiz-de Gopegui R, Montané J, Muñoz S, Ferre T. Treatment of diabetes and long-term survival after insulin and glucokinase gene therapy. Diabetes. 2013; 62(5): 1718-1729. https://doi.org/10.2337/db12-1113
64. Yechoor V, Chan L. Gene therapy progress and prospects: gene therapy for diabetes mellitus. Gene Ther. 2005; 12(2): 101-7. https://doi.org/10.1038/sj.gt.3302412
65. Zhang ZH, Barajas-Martinez H, Jiang H, Huang CX, Antzelevitch C, Xia H, Hu D. Gene and stem cell therapy for inherited cardiac arrhythmias. Pharmacol Ther. 2024; 256: 108596. https://doi.org/10.1016/j.pharmthera.2024.108596
66. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin. Med. Res. 2006; 4(3): 218- 227. https://doi.org/10.3121/cmr.4.3.218
67. Newgard CB. Cellular engineering and gene therapy strategies for insulin replacement in diabetes. Diabetes. 1994; 43(3): 341-350. https://doi.org/10.2337/diab.43.3.341
68. Amariutei AE, Jeng JY, Safieddine S, Marcotti W. Recent advances and future challenges in gene therapy for hearing loss. R Soc Open Sci. 2023; 10(6): 230644. https://doi.org/10.1098/rsos.230644
69. Jiang L, Wang D, He Y, Shu Y. Advances in gene therapy hold promise for treating hereditary hearing loss. Mol Ther. 2023; 31(4): 934-950. https://doi.org/10.1016/j.ymthe.2023.02.001
70. Omichi R, Shibata SB, Morton CC, Smith RJ. Gene therapy for hearing loss. Hum Mol Genet. 2019; 28(R1): R65-79. https://doi.org/10.1093/hmg/ddz129
71. Chien WW, Monzack EL, McDougald DS, Cunningham LL. Gene therapy for sensorineural hearing loss. Ear Hear. 2015; 36(1): 1-7. https://doi.org/10.1097/aud.0000000000000088
72. Singh K, Sethi P, Datta S, Chaudhary JS, Kumar S, Jain D, Gupta JK, Kumar S, Guru A, Panda SP. Advances in gene therapy approaches targeting neuro-inflammation in neurodegenerative diseases. Ageing Res Rev. 2024;98:102321. https://doi.org/10.1016/j.arr.2024.102321
73. Carpena NT, Lee MY. Genetic hearing loss and gene therapy. Genomics Inform. 2018;16(4):e20. https://doi.org/10.5808/GI.2018.16.4.e20
74. Nourbakhsh A, Colbert BM, Nisenbaum E, El-Amraoui A, Dykxhoorn DM, Koehler KR, Chen ZY, Liu XZ. Stem cells and gene therapy in progressive hearing loss: the state of the art. J Assoc Res Otolaryngol. 2021; 22: 95-105. https://doi.org/10.1007/s10162-020-00781-0
75. Vlekkert DVD, Hu H, Weesner JA, Fremuth LE, Brown SA, Lu M. AAV-mediated gene therapy for sialidosis. Mol Ther. 2024; 32(7): 2094-2112. https://doi.org/10.1101/2023.11.10.566667
76. Doshi BS, Samelson-Jones BJ, Nichols TC, Merricks EP, Siner JL. AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life. Mol Ther Methods Clin Dev. 2024; 32(1): 101205. https://doi.org/10.1016/j.omtm.2024.101205
77. Muczynski V, Nathwani AC. AAV mediated gene therapy for haemophilia B: From the early attempts to modern trials. Thromb Res. 2024; 236: 242-249. https://doi.org/10.1016/j.thromres.2020.12.033
78. Gardin A, Ronzitti G. Current limitations of gene therapy for rare pediatric diseases: Lessons learned from clinical experience with AAV vectors. Arch Pediatr. 2023; 30(8-1): 8S46-8S52. https://doi.org/10.1016/s0929-693x(23)00227- 0
79. Duan M, Venail F, Spencer N, Mezzina M. Treatment of peripheral sensorineural hearing loss: gene therapy. Gene Ther. 2004; 11(1): S51-56. https://doi.org/10.1016/s0929-693x(23)00227-0
80. Zhang W, Kim SM, Wang W, Cai C, Feng Y, Kong W, Lin X. Cochlear gene therapy for sensorineural hearing loss: current status and major remaining hurdles for translational success. Front Mol Neurosci. 2018; 11: 221. https://doi.org/10.3389/fnmol.2018.00221
81. Gallo V, Aiuti A. Gene therapy for rare haematological and neurometabolic paediatric diseases. Glob Pediatr. 2024; 9(4): 100196. http://dx.doi.org/10.1016/j.gpeds.2024.100196
82. Rossi A, Malvagia S, Marca GL, Parenti G, Brunetti-Pierri N. Biomarkers for gene therapy clinical trials of lysosomal storage disorders. Mol Ther. 2024; 32(9): 2930-2938. https://doi.org/10.1016/j.ymthe.2024.06.003
83. Bremond-Gignac D, Robert MP, Daruich A. Update on gene therapies in pediatric ophthalmology. Arch Pediatr. 2023; 30(8): 8S41-8S45. https://doi.org/10.1016/s0929-693x(23)00226-9 Li B, Tan W, Wang Z, Zhou H, Zou J, Li Y. Progress and prospects of gene therapy in ophthalmology from 2000 to 2022: A bibliometric analysis. Heliyon. 2023; 9(7): e18228. https://doi.org/10.1016/j.heliyon.2023.e18228
84. Li S, Ling S, Wang D, Wang X, Hao F. Modified lentiviral globin gene therapy for pediatric β0/β0 transfusion- dependent β-thalassemia: A single-center, single-arm pilot trial. Cell Stem Cell. 2024; 31(7): 961-973.e8.
85. Sangster ML, Bishop MM, Yao Y, Feitor JF, Shahriar S, Miller ME. A blood-brain barrier-penetrant AAV gene therapy improves neurological function in symptomatic mucolipidosis IV mice. Mol Ther Methods Clin Dev. 2024; 32(2): 101269. https://doi.org/10.1016/j.omtm.2024.101269
86. Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF, Soffer EB, Mondkar S, King GD, Hu J, Sciascia SA. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther. 2005; 12(2): 189-211. https://doi.org/10.1016/j.ymthe.2005.03.022
87. Mével M, Pichard V, Bouzelha M, Dorta DA, Lalys P, Provost N. Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency. Mol Ther Methods Clin Dev. 2024; 32(2): 101261. https://doi.org/10.1016/j.omtm.2024.101187
88. Graves LE, Dijk EBV, Zhu E, Koyyalamudi S, Wotton T, Sung D. AAV-delivered hepato-adrenal cooperativity in steroidogenesis: Implications for gene therapy for congenital adrenal hyperplasia. Mol Ther Methods Clin Dev. 2024; 32(2): 101232. https://doi.org/10.1016/j.omtm.2024.101232
89. Broeders M, Herrero-Hernandez P, Ernst MP, van der Ploeg AT, Pijnappel WP. Sharpening the molecular scissors: advances in gene-editing technology. Science. 2020; 23(1): 100789. https://doi.org/10.1016/j.isci.2019.100789
90. Lemmens M, Dorsheimer L, Zeller A, Dietz-Baum Y. Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapies. Mutat Res Genet Toxicol Environ Mutagen. 2024; 869: 503767. https://doi.org/10.1016/j.mrgentox.2024.503767
91. Gonçalves GA, Paiva RD. Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo). 2017; 15: 369- 375. https://doi.org/10.1590/S1679-45082017RB4024
92. Xu C, Zhang X, Yang W, Gao S, Zhao N, Li P, Du J, Li Y, Xu FJ. Effective prevention of atherosclerosis by non-viral delivery of CRISPR/Cas9. Nano Today. 2024; 54: 102097. http://dx.doi.org/10.1016/j.nantod.2023.102097
93. Meng H, Nan M, Li Y, Ding Y, Yin Y, Zhang M. Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer. Front Endocrinol. 2023; 14: 1148412. https://doi.org/10.3389/fendo.2023.1148412
94. Evangelidis N, Evangelidis P. Gene Therapy for Hypertension, Atherosclerosis, and Familial Hypercholesterolemia: The Old Concepts and the New Era. Biologics. 2024; 4(2): 143-160. https://doi.org/10.3390/biologics4020010
95. Bevacqua RJ, Zhao W, Merheb E, Kim SH, Marson A, Gloyn AL, Kim SK. Multiplexed CRISPR gene editing in primary human islet cells with Cas9 ribonucleoprotein. iScience. 2023;27(1):108693. https://doi.org/10.1101/2023.09.16.558090
96. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014; 157(6): 1262-1278. https://doi.org/10.1016/j.cell.2014.05.010
97. Giannoukakis N, Rudert WA, Robbins PD, Trucco M. Targeting autoimmune diabetes with gene therapy. Diabetes. 1999; 48(11): 2107-2121. https://doi.org/10.2337/diabetes.48.11.2107
98. Bhatia R, Singh A, Singh S, Rawal RK. Emerging trends in nano-carrier based gene delivery systems for targeted cancer therapy. J Drug Deliv Technol. 2024; 95: 105546. http://dx.doi.org/10.1016/j.jddst.2024.105546
99. Espuche B, Moya SE, Calderón M. Nanogels: Smart tools to enlarge the therapeutic window of gene therapy. Int J Pharm. 2024; 653: 123864. https://doi.org/10.1016/j.ijpharm.2024.123864
100. Tanguy OB, Sevin C, Piguet F. Gene therapy for neurodegenerative disorders in children: dreams and realities. Arch Pediatr. 2023; 30(8-1): 8S32-8S40. https://doi.org/10.1016/s0929-693x(23)00225-7